{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:40:25Z","timestamp":1760182825957,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.rdc.2011.07.007","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T17:50:47Z","timestamp":1319737847000},"page":"323-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment?"],"prefix":"10.1016","volume":"37","author":[{"given":"Andrew J.","family":"Laster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Bobo","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rdc.2011.07.007_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.rdc.2011.07.007_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.rdc.2011.07.007_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.rdc.2011.07.007_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00198-008-0813-x","article-title":"To stop or not to stop, that is the question","volume":"20","author":"Seeman","year":"2009","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.rdc.2011.07.007_bib5","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.rdc.2011.07.007_bib6","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.103","article-title":"Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial","volume":"25","author":"Grey","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.rdc.2011.07.007_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.rdc.2011.07.007_bib8","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.rdc.2011.07.007_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","article-title":"Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women","volume":"103","author":"Stock","year":"1997","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.rdc.2011.07.007_bib10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbmr.5650091121","article-title":"Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis","volume":"9","author":"Rossini","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.rdc.2011.07.007_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.rdc.2011.07.007_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.007_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2011.07.007_bib14","first-page":"S22","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial","volume":"25","author":"Black","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"22","key":"10.1016\/j.rdc.2011.07.007_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2011.07.007_bib16","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group","volume":"85","author":"Tonino","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.rdc.2011.07.007_bib17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.rdc.2011.07.007_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2011.07.007_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-008-0766-0","article-title":"Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis","volume":"20","author":"Lindsay","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rdc.2011.07.007_bib20","article-title":"The effect of 3 versus 6 years of zolendronic acid treatment in osteoporosis: a randomized extension in the HORIZON-pivotal fracture trial (PFT)","author":"Black","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"8228","key":"10.1016\/j.rdc.2011.07.007_bib21","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(81)92215-7","article-title":"Bone mass after withdrawal of oestrogen replacement","volume":"1","author":"Christiansen","year":"1981","journal-title":"Lancet"},{"issue":"8218","key":"10.1016\/j.rdc.2011.07.007_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(81)91848-1","article-title":"Bone mass in postmenopausal women after withdrawal of oestrogen\/gestagen replacement therapy","volume":"1","author":"Christiansen","year":"1981","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.rdc.2011.07.007_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"issue":"16","key":"10.1016\/j.rdc.2011.07.007_bib24","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJM199310143291610","article-title":"The waning effect of postmenopausal estrogen therapy on osteoporosis","volume":"329","author":"Ettinger","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.rdc.2011.07.007_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJM199310143291601","article-title":"The effect of postmenopausal estrogen therapy on bone density in elderly women","volume":"329","author":"Felson","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2011.07.007_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s001980170107","article-title":"Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women","volume":"12","author":"Tremollieres","year":"2001","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.007_bib27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bone.2009.10.043","article-title":"The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women","volume":"46","author":"Naylor","year":"2010","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.rdc.2011.07.007_bib28","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.rdc.2011.07.007_bib29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"issue":"18","key":"10.1016\/j.rdc.2011.07.007_bib30","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2011.07.007_bib31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.rdc.2011.07.007_bib32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1359\/jbmr.080510","article-title":"Fracture outcomes related to persistence and compliance with oral bisphosphonates","volume":"23","author":"Gallagher","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.rdc.2011.07.007_bib33","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday","volume":"19","author":"Curtis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.rdc.2011.07.007_bib34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women","volume":"305","author":"Park-Wyllie","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.rdc.2011.07.007_bib35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.rdc.2011.07.007_bib36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/AOG.0b013e3181d41191","article-title":"Role of hormone therapy in the management of menopause","volume":"115","author":"Shifren","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.007_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"6 Pt 1","key":"10.1016\/j.rdc.2011.07.007_bib38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.rdc.2011.07.007_bib39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.007_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.AOG.0000114986.14806.37","article-title":"Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment","volume":"103","author":"Yates","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.rdc.2011.07.007_bib41","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over eight years in a clinical trial setting","volume":"21","author":"Martino","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 4","key":"10.1016\/j.rdc.2011.07.007_bib42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/gme.0b013e31817e6683","article-title":"Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women","volume":"15","author":"Olevsky","year":"2008","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.rdc.2011.07.007_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbspin.2006.05.011","article-title":"How long should patients take medications for postmenopausal osteoporosis?","volume":"74","author":"Briot","year":"2007","journal-title":"Joint Bone Spine"},{"issue":"8","key":"10.1016\/j.rdc.2011.07.007_bib44","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2011.07.007_bib45","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.rdc.2011.07.007_bib46","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.rdc.2011.07.007_bib47","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2011.07.007_bib48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/17453670903139914","article-title":"Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate","volume":"80","author":"Schilcher","year":"2009","journal-title":"Acta Orthop"},{"key":"10.1016\/j.rdc.2011.07.007_bib49","unstructured":"Dell R, Greene D, Ott S, et al. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. ASBMR Annual Meeting. Toronto, Canada, 2010. p. S61 [abstract: 1201]."},{"issue":"11","key":"10.1016\/j.rdc.2011.07.007_bib50","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"19","key":"10.1016\/j.rdc.2011.07.007_bib51","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.rdc.2011.07.007_bib52","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.007_bib53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996\u20132007","volume":"26","author":"Wang","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.007_bib54","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1377\/hlthaff.26.3.741","article-title":"Numeracy skill and the communication, comprehension, and use of risk-benefit information","volume":"26","author":"Peters","year":"2007","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.007_bib55","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1377\/hlthaff.26.3.636","article-title":"What\u2019s more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits)","volume":"26","author":"Cohen","year":"2007","journal-title":"Health Aff (Millwood)"},{"issue":"12","key":"10.1016\/j.rdc.2011.07.007_bib56","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1359\/jbmr.090527","article-title":"Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate","volume":"24","author":"Dobnig","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.rdc.2011.07.007_bib57","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00198-009-1168-7","article-title":"Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis","volume":"21","author":"Stepan","year":"2010","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.rdc.2011.07.007_bib58","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.198","article-title":"Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate","volume":"25","author":"Misof","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9","key":"10.1016\/j.rdc.2011.07.007_bib59","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7326\/0003-4819-153-9-201011020-00007","article-title":"A\u00a0before-and-after study of fracture risk reporting and osteoporosis treatment initiation","volume":"153","author":"Leslie","year":"2010","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2011.07.007_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/gme.0b013e3181e77468","article-title":"Simplifying screening for osteoporosis in Australian primary care: the Prospective Screening for Osteoporosis; Australian Primary Care Evaluation of Clinical Tests (PROSPECT) study","volume":"18","author":"Davis","year":"2011","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.rdc.2011.07.007_bib61","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.berh.2005.06.007","article-title":"Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?","volume":"19","author":"Sambrook","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X11000342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X11000342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:09:37Z","timestamp":1760180977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X11000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0889857X11000342"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2011.07.007","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment?","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2011.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}